WuXi AppTec’s US Medical Device Testing Operations Is Now NAMSA

NAMSA Now Offers Broader Array of Services

On February 28, 2025, NAMSA completed its acquisition of WuXi AppTec’s US medical device testing operations. What does this mean to you? It means that together we now offer you access to more scientists, more lab capacity and more experience with a wider range medical devices than any other lab worldwide. By combining our strengths, NAMSA now offers the most comprehensive and reliable medical device testing, clinical research and consulting services.

1. Access to Unmatched Scientific Expertise in Biological Safety​

NAMSA helps more medical device manufacturers with biocompatibility testing than any other lab. By adding WuXi’s expert team and capabilities, we can now expand that claim to Extractables and Leachables (E&L) testing as well. The benefit to you is access to the deepest bench of biological safety specialists and toxicologists at our US and European facilities, all of whom are ready to work with you to develop a plan tailored to your specific medical device and regulatory pathway. ​

2. Shorten Your Overall Time to Market​

More than 70% of all global biocompatibility studies are conducted by NAMSA. This matters because NAMSA has seen and tested nearly every conceivable device. We know what testing is required and our results are trusted by US, EU and other regulators. This means you can proceed to the next stage faster. Instead of engaging multiple labs to perform preclinical, biocompatibility, E&L and microbiology testing, you can save valuable time working with NAMSA. ​

3. Get Your Test Results Quickly​

With the addition of WuXi facilities in the US, we now offer you more capacity than every before. We schedule quickly, complete efficiently, and deliver accurate results the first time. In addition, we offer extensive microbiological capabilities with labs in the US Midwest, Southeast and West Coast.